Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,350 INR | -0.48% | +2.69% | -0.42% |
16/04 | Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution | MT |
28/03 | Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication | MT |
Sales 2024 * | 16.92B 203M | Sales 2025 * | 19.11B 229M | Capitalization | 103B 1.23B |
---|---|---|---|---|---|
Net income 2024 * | 4.57B 54.82M | Net income 2025 * | 4.17B 50.04M | EV / Sales 2024 * | 6.06 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.37 x |
P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
20.9
x | Employees | 1,642 |
Yield 2024 * |
0.23% | Yield 2025 * |
0.25% | Free-Float | 25.33% |
Latest transcript on Caplin Point Laboratories Limited
1 day | -0.48% | ||
1 week | +2.69% | ||
Current month | +2.52% | ||
1 month | +7.18% | ||
3 months | -6.61% | ||
6 months | +32.79% | ||
Current year | -0.42% |
Managers | Title | Age | Since |
---|---|---|---|
Sridhar Ganesan
CEO | Chief Executive Officer | 69 | 28/15/28 |
D. Muralidharan
DFI | Director of Finance/CFO | - | 19/16/19 |
Anto V.
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | - | |
Chief Operating Officer | - | 01/10/01 | |
Sridhar Ganesan
CEO | Chief Executive Officer | 69 | 28/15/28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 117 M€ | +1.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1,350 | -0.48% | 5,184 |
25/24/25 | 1,357 | +1.86% | 5,978 |
24/24/24 | 1,332 | -0.15% | 4,419 |
23/24/23 | 1,334 | -0.03% | 2,793 |
22/24/22 | 1,335 | +1.49% | 14,998 |
Delayed Quote Bombay S.E., April 26, 2024 at 03:30 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.42% | 1.23B | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- CAPLIPOINT Stock